Cite

HARVARD Citation

    Kopruszinski, C. et al. (2020). Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine. Cephalalgia. pp. 1535-1550. [Online]. 
  
Back to record